{"id":751150,"date":"2023-04-25T18:35:29","date_gmt":"2023-04-25T22:35:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/"},"modified":"2023-04-25T18:35:29","modified_gmt":"2023-04-25T22:35:29","slug":"data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/","title":{"rendered":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <em>Findings support <\/em><br \/>\n          <em>A\u03b2 vaccine<\/em><br \/>\n          <em>candidate <\/em><br \/>\n          <em>consisting of conformational<\/em><br \/>\n          <em>B cell epitope<\/em><br \/>\n          <em> of A\u03b2 oligomers<\/em><br \/>\n          <em> conjugated to a carrier protein <\/em><br \/>\n          <em>as a potential <\/em><br \/>\n          <em>strategy for <\/em><br \/>\n          <em>preventing<\/em><br \/>\n          <em> Alzheimer\u2019s disease<\/em><br \/>\n          <em> progression<\/em>\n        <\/li>\n<\/ul>\n<p>TORONTO, Ontario and CAMBRIDGE, Massachusetts, April  25, 2023  (GLOBE NEWSWIRE) &#8212;  ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (A\u03b2) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting.<\/p>\n<p>The Company believes that a vaccination strategy for the prevention or treatment of AD, compared to passive immunization with a therapeutic antibody, could present several potential advantages, including the potential for sustained anti-disease activity and ease of use for prevention in conjunction with diagnostic biomarkers, and fewer doses compared with chronic antibody treatment. An AD vaccine capable of inducing an effective antibody response against pathogenic A\u03b2 could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD. Using computational modeling, ProMIS has identified conformational epitopes that are exposed on misfolded, toxic A\u03b2 oligomers (A\u03b2O), the driver of disease, and not on monomers or plaque. In mouse preclinical studies, vaccination with a conformational A\u03b2O epitope conjugated to a carrier protein and delivered with adjuvant induced a strong, sustained antibody response with the desired oligomer selectivity.<\/p>\n<p>\u201cThese encouraging data support our approach of immunization with a rationally designed vaccine consisting of an A\u03b2 oligomer conformational B cell epitope conjugated to a carrier protein,\u201d said Johanne Kaplan, Ph.D., Chief Development Officer of ProMIS Neurosciences and first author of the presentation. \u201cWe look forward to advancing our goal of developing a safe and effective AD vaccine to induce a specific immune response against toxic A\u03b2 oligomers.\u201d<\/p>\n<p>In an oral presentation titled, \u201cRational design of a vaccine for Alzheimer\u2019s disease using computationally-derived conformational B cell epitopes to selectively target toxic amyloid-beta oligomers,\u201d mouse studies were conducted to assess the potential of ProMIS\u2019 vaccine candidate designed to induce A\u03b2O-restricted antibodies without eliciting potentially inflammatory T cell responses against A\u03b2 in the brain (meningoencephalitis). The ProMIS vaccine candidate, consisting of an A\u03b2O conformational peptide epitope conjugated to KLH as a carrier protein to provide T cell help, elicited robust and sustained antibody responses with either alum or QS-21 as the adjuvants. There were no potentially deleterious T helper cell responses to the conformational A\u03b2O peptide epitope, and T helper responses developed only against the KLH carrier protein. In addition, the serum antibodies elicited were selective for A\u03b2O with no detectable binding to monomers or plaque, which could reduce the risk of amyloid-related imaging abnormalities (ARIA) associated with plaque-binding antibodies. These findings support potential clinical development of a therapeutic vaccine for AD that could elicit an antibody response while reducing the risk of meningoencephalitis, as well as ARIA.<\/p>\n<p>The slide presentation is available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xANQ7Mi8e8RaRr9KApNTq1kskbmGCg7FP620YzURM2wrtHbxk9QeOEds9BFJYox9oGvKStaeaNZ8PI5jtcJSp_44v2FARps0yRVo2CX4Wz4oPG7PTVMFZwYYYU72ZG5IgMbbpZVda_wd-i0LKHQ7pYyDxwhJMVOJjyxE_1dOKHM=\" rel=\"nofollow noopener\" target=\"_blank\">Posters and Publications<\/a> page of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R06IipoAJIjgWBvnHDLcA99h7tjSqolxnEl0sGymaz8t67OXcOpSAaj6Vy6fCq-Ebud3wglkIBDR8abwU7zbEM7yHHbcbRK9IEURd6yDRJj71O8EZmQkKTX7HjRmGJaw\" rel=\"nofollow noopener\" target=\"_blank\">www.promisneurosciences.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About ProMIS Neurosciences Inc.<\/strong>\n      <\/p>\n<p>ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company\u2019s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform &#8211; ProMIS\u2122 and Collective Coordinates &#8211; to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Neither the TSX nor Nasdaq has reviewed and neither accepts responsibility for the adequacy or accuracy of this release.\u00a0Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, \u200e\u200e\u201cforward-looking information\u201d) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the \u200euse of forward-looking terminology such as \u201cplans\u201d, \u201ctargets\u201d, \u201cexpects\u201d or \u201cdoes not expect\u201d, \u201cis expected\u201d, \u201can opportunity exists\u201d, \u200e\u200e\u201cis positioned\u201d, \u201cestimates\u201d, \u201cintends\u201d, \u201cassumes\u201d, \u201canticipates\u201d or \u201cdoes not anticipate\u201d or \u201cbelieves\u201d, or variations of such words and \u200ephrases or state that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d, \u201cwill\u201d or \u201cwill be taken\u201d, \u201coccur\u201d or \u201cbe \u200eachieved\u201d. In addition, any statements that refer to expectations, projections or other characterizations of future events or \u200ecircumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to targeting of toxic misfolded proteins that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of amyloid-beta are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity, ProMIS\u2019 pipeline, statements regarding a computationally-derived amyloid-beta (A\u03b2) vaccine for AD and the Company\u2019s vaccine candidate, management\u2019s belief that its patented platform technology has created an antibody candidate specific to toxic misfolded oligomers known to be present in Alzheimer\u2019s disease, and management\u2019s belief that this specificity may indicate greater therapeutic potential due to lower off-target activity and reduce the risk of brain edema and microhemorrhages (ARIA) associated with plaque-binding antibodies. Statements containing forward-looking\u00a0information are not historical facts but instead represent management&#8217;s current \u200eexpectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events \u200eand trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to \u200eknown and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, \u200eperformance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the Company\u2019s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the \u201cRisk Factors\u201d section of the Company&#8217;s most recently filed annual information form available on www.SEDAR.com, in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2022 and the section entitled \u201cRisk Factors\u201d in its Post-Effective Amendment No. 1 to Form S-1, filed March 17, 2023, each as filed with the Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p align=\"justify\">For further information:<\/p>\n<p align=\"justify\">Visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R06IipoAJIjgWBvnHDLcA99h7tjSqolxnEl0sGymaz_oe_AHRZRMTCS4_T8XBZufXhm-Q1cCk2nMB611wab70KXBPpX901aeDntG3gsuiUFPNbganTpJvj65zYzIQZ2c\" rel=\"nofollow noopener\" target=\"_blank\">www.promisneurosciences.com<\/a><\/p>\n<p align=\"justify\">Please submit media inquiries to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PQp662uSH9kRdyN3WKrQXHbVD-KTI35UsWhEmFTVPeVRhPHy_XCgevtPrClj2Kz9s5Jyzk1fUonLXT3eHVSQjN4c4gEFJbDPMXMSNk9jcdiGJB_eUSW_PDRgjGWuDWpu\" rel=\"nofollow noopener\" target=\"_blank\">info@promisneurosciences.com<\/a>.<\/p>\n<p align=\"justify\">For Investor Relations, please contact: <br \/>Stern Investor Relations<br \/>Suzanne Messere, Managing Director<br \/>suzanne.messere@sternir.com<br \/>Tel. 212-698-8801<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MmJhY2E2MjAtNGNkMC00ZWYzLThlMjEtYzg2NDYzMjYzMmRmLTEwOTYxNjA=\/tiny\/ProMIS-Neurosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Findings support A\u03b2 vaccine candidate consisting of conformational B cell epitope of A\u03b2 oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer\u2019s disease progression TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 25, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (A\u03b2) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting. The Company believes that a vaccination strategy for the prevention or treatment of AD, compared to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751150","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Findings support A\u03b2 vaccine candidate consisting of conformational B cell epitope of A\u03b2 oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer\u2019s disease progression TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 25, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (A\u03b2) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting. The Company believes that a vaccination strategy for the prevention or treatment of AD, compared to &hellip; Continue reading &quot;Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T22:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease\",\"datePublished\":\"2023-04-25T22:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/\"},\"wordCount\":1226,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/\",\"name\":\"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\",\"datePublished\":\"2023-04-25T22:35:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk","og_description":"Findings support A\u03b2 vaccine candidate consisting of conformational B cell epitope of A\u03b2 oligomers conjugated to a carrier protein as a potential strategy for preventing Alzheimer\u2019s disease progression TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 25, 2023 (GLOBE NEWSWIRE) &#8212; ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer\u2019s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (A\u03b2) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting. The Company believes that a vaccination strategy for the prevention or treatment of AD, compared to &hellip; Continue reading \"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T22:35:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease","datePublished":"2023-04-25T22:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/"},"wordCount":1226,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/","name":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=","datePublished":"2023-04-25T22:35:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTQ2OSM1NTU3MTI2IzIwODQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-presented-at-american-academy-of-neurology-annual-meeting-on-novel-vaccine-design-for-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751150"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751150\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}